Can Ozempic Fix Our Obesity Crisis?

View the Show Notes For This Episode Get Free Weekly Health Tips from Dr. Hyman Sign Up for Dr. Hyman’s Weekly Longevity Journal Get Ad-free Episodes & Dr. Hyman+ Audio Exclusives Ozempic and other GLP-1 agonists like Wegovy have exploded as “miracle weight loss drugs.” But as the research unfolds, we’re quickly discovering that these drugs are not risk free and come with some very concerning side effects. In today’s episode of my series I’m calling Health Bites, I dive deep into the complexities of Ozempic. From nationwide shortages, high costs, the lack of insurance coverage, and severe, somewhat common, side effects, I explore the hurdles of Ozempic and question if it's truly a sustainable solution to our growing obesity crisis. This episode is brought to you by Mitopure and Cozy Earth. Support essential mitochondrial health and save 10% on Mitopure. Visit TimelineNutrition.com/Drhyman and use code DRHYMAN10. Right now, you can save 40% when you upgrade to Cozy Earth sheets. Just head over to CozyEarth.com and use code DRHYMAN. Here are more details from the episode (audio version / Apple Subscriber version): Current and potential uses for Ozempic and GLP-1 (6:42 / 4:01) Common side effects from Ozempic (8:48 / 6:07) Understanding the obesity and chronic disease crisis (9:33 / 6:52) Long-term risks associated with Ozempic (14:47 / 12:06) Combatting the idea that obesity is genetic (17:54 / 15:13) Can you be healthy at any size? (20:37 / 17:55) How traditional medicine misses the mark in addressing obesity (24:36 / 21:55) Clinical research findings of Ozempic use (31:44 / 29:03) Addressing the root cause of obesity and type 2 diabetes (35:34 / 32:53) Mentioned in this episode Dr. Hyman’s Free Sleep Masterclass Function Health The 10-day Detox Diet Connect with Dr. Mark Hyman on Twitter, Instagram, Facebook, and YouTube

Im a fan of Dr Hymen, but this episode misses the Mark

I’m an MD dedicated to promoting wellness and quality of life. I agree that optimal health begins with a healthy lifestyle. For many these measures alone fall short in preventing metabolic syndrome, obesity, and its toll of chronic debilitating disease. Semaglutide is a rationale option for this group, promising to profound reduce their rates of stroke and heart-related death as well as achieve significant, sustained weight loss with negligible risk.
The medical literature suggests the incidence of severe complications is extremely low, well below 1% for pancreatitis, and even lower for bowel obstruction and gastroparesis.
Nausea and diarrhea are more common but transient and not debilitating for most patients. Furthermore these adverse events cease when the medicine is discontinued.
Dr Hymen argues that the cost of Semaglutide is a burden on our healthcare system. The converse is actually true. Semaglutide has the potential to profoundly improve Americans health, reducing healthcare costs exponentially.
And while Semaglutide is in short supply and retail price is over $1,000 / month that price will likely plummet soon as competition ensues and supply meets demand. Even now, reputable compound pharmacies can provide this medicine for under $300. Some insurance companies are covering Semaglutide, and the market will drive most of them to cover it soon. My hat is off to Dr Hymen for trying to improve our health. I believe with time he will become an advocate for Semaglutide.